Literature DB >> 17038537

Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients.

Chun Fu Zheng1, Ling Ling Ma, Gareth J Jones, M John Gill, Alan M Krensky, Paul Kubes, Christopher H Mody.   

Abstract

An important mechanism of host defense to Cryptococcus neoformans involves the direct microbicidal activity of lymphocytes. The importance of CD4+ T cells is illustrated by the incidence of this infection in the acquired immunodeficiency syndrome (AIDS) patients; however, the relative activity of microbicidal CD4+ T cells compared with CD8+ T cells and natural killer (NK) cells has not been established. Further, although NK cells and CD8+ T cells use perforin or granulysin, respectively, to kill C neoformans, the effector molecule used by CD4+ T cells is not known. Experiments demonstrated that IL-2-activated peripheral blood lymphocytes from healthy adults acquire anticryptococcal activity, and surprisingly, that CD4+ T cells had the most profound effect on this activity. Using SrCl(2)induced degranulation and siRNA knockdown, granulysin was shown to be the effector molecule. Although activation by anti-CD3 + IL-2 resulted in the additional expression of perforin, this did not improve the anticryptococcal activity. Cryptococcal killing by CD4+ T cells was defective in human immunodeficiency virus (HIV)-infected patients due to dysregulated granulysin and perforin production in response to IL-2 or anti-CD3 + IL-2. In conclusion, CD4+ T cells are the major subset of cells responsible for killing C neoformans in peripheral blood. These cells use granulysin as the effector molecule, and priming is dysregulated in HIV-infected patients, which results in defective microbicidal activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038537     DOI: 10.1182/blood-2006-03-009720

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.

Authors:  Deborah M Brown
Journal:  Cell Immunol       Date:  2010-02-24       Impact factor: 4.868

2.  Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors:  Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

3.  Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy.

Authors:  Luc Kestens; Nabila Seddiki; Paul R Bohjanen
Journal:  Curr Opin HIV AIDS       Date:  2008-07       Impact factor: 4.283

4.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

5.  Human yeast-specific CD8 T lymphocytes show a nonclassical effector molecule profile.

Authors:  Tanja Breinig; Nicoletta Scheller; Birgit Glombitza; Frank Breinig; Andreas Meyerhans
Journal:  Med Microbiol Immunol       Date:  2011-09-25       Impact factor: 3.402

Review 6.  Granulysin: killer lymphocyte safeguard against microbes.

Authors:  Farokh Dotiwala; Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2019-05-18       Impact factor: 7.486

Review 7.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

8.  IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.

Authors:  Wendy A Szymczak; Rani S Sellers; Liise-anne Pirofski
Journal:  Am J Pathol       Date:  2012-02-16       Impact factor: 4.307

9.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

Review 10.  Direct microbicidal activity of cytotoxic T-lymphocytes.

Authors:  Paul Oykhman; Christopher H Mody
Journal:  J Biomed Biotechnol       Date:  2010-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.